Press release
CD Bioparticles Announces Comprehensive Assay Portfolio for mRNA-LNP Vaccine Development
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is pleased to announce a suite of comprehensive mRNA-LNP Vaccine [https://www.cd-bioparticles.net/services/bioparticles-analysiscand-characterization/mrna-lnp-vaccine-laboratory-process-development-assay] Laboratory Process Development Assays. This latest addition to CD Bioparticles' extensive service portfolio is specifically designed for the rapid and efficient development of mRNA-LNP vaccines.
The mRNA molecule is well known to the public through COVID-19 and the mRNA vaccine made from it is characterized by rapid blocking of pathogen mutation response, simple production process and scale-up. Detection and validation methods are the basis for quality control of mRNA LNP vaccines. Therefore, R&D companies should establish detection methods for the characteristics of mRNA, liposomes and formulations, as well as related impurities and other key quality attributes of mRNA vaccines to ensure the safety and efficacy of mRNA-LNP vaccines.
CD Bioparticles now offers a comprehensive portfolio of laboratory assays designed to support every stage of mRNA-LNP vaccine development. These assays provide researchers with the tools they need to optimize their vaccine formulations and ensure their safety and efficacy, accelerating the path to clinical trials and commercialization. In addition, CD Bioparticles' team of scientific experts is available to work with researchers to develop custom assays to meet their specific needs.
CD Bioparticles mRNA-LNP vaccine assay portfolio encompasses a variety of methodologies, including Cellular Uptake Studies,mRNA Transfection Efficiency Study, In Vivo Biodistribution, Histopathological Studies, Biochemical Indicators Testing, and Detection of Antigen-Specific T Cells. By leveraging CD Bioparticles' expertise in analysis and characterization, researchers can gain deeper insights into the properties and performance of their vaccines, enabling them to make informed decisions during the development process.
For example, in the mRNA Transfection Efficiency Study, DC2.4 cells are selected as the model cells for the infection experiment. After infecting the cells with GFP-mRNA-LNP, the intracellular GFP signal will be observed by fluorescence microscopy. CD Bioparticles can assist customers with immunostaining studies that not only examine the efficiency of mRNA transmission, but also help to identify the specific cell types that are transfected into a specific type of organ.
CD Bioparticles also offers In Vivo Biodistribution services. To visualize the distribution of LNP in an organism, the professionals use fluorescent dyes (e.g., DiD and DiO) and luciferase for labeling. Typically, luciferase mRNA (Luc-mRNA) is used as a model mRNA to follow the distribution of the expressed protein in vivo. After intravenous injection of Luc-mRNA-LNP, heart, liver, spleen, lung, kidney and lymph node tissues are isolated. The tissues will be visualized using the IVIS Spectral Live Image System. This will facilitate visualization studies of organ distribution and duration of protein activity production.
CD Bioparticles' new mRNA-LNP assays are available to researchers and vaccine developers worldwide. The company is committed to providing cutting-edge technologies and services that support the advancement of biotechnology and improve human health. For more information about the services, please visit https://www.cd-bioparticles.net/services/bioparticles-analysiscand-characterization/mrna-lnp-vaccine-laboratory-process-development-assay.
About CD Bioparticles
CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.
Media Contact
Company Name: CD Bioparticles
Contact Person: Richard J. Gray
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cd-bioparticles-announces-comprehensive-assay-portfolio-for-mrnalnp-vaccine-development]
State: New York
Country: United States
Website: https://www.cd-bioparticles.net/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CD Bioparticles Announces Comprehensive Assay Portfolio for mRNA-LNP Vaccine Development here
News-ID: 3506683 • Views: …
More Releases from ABNewswire
Affordable Roofing Systems, a Roofing Company in Town 'N' Country, FL, Serves Lo …
TOWN 'N' COUNTRY, FL - Since 2002, Affordable Roofing Systems has been recognized as a leading roofing company serving Town 'N' Country, FL [https://www.affordableroofingflorida.com/local-roofing-companies/roofer-town-n-country/], with a long-standing presence across the greater Tampa Bay region. With over two decades of experience, the company has established a reputation for delivering high-quality workmanship on both residential and commercial roofing projects. From addressing missing shingles to performing full roof replacements, Affordable Roofing Systems remains…
Diabetic Retinopathy Market Positioned for Accelerated Development Through 2034, …
The Key Diabetic Retinopathy Companies in the market include - Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd., Kodiak Sciences Inc, and others.
DelveInsight's "Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the…
T-cell receptor (TCR) Therapy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and C …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, T-cell receptor (TCR) Therapy pipeline constitutes key companies continuously working towards developing T-cell receptor (TCR) Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"T-cell receptor (TCR) Therapy Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/t-cell-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the T-cell receptor (TCR)…
ESR1 Mutated Metastatic Breast Cancer Market to Witness Promising Upswing by 203 …
The Key ESR1 Mutated Metastatic Breast Cancer Companies in the market include - AstraZeneca, Sermonix Pharmaceuticals, Sun Pharma Advanced Research Company, Radius Pharmaceuticals/ Menarini Group, Pfizer, G1 Therapeutics, Sanofi, Sun PharmaAdvanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine/ Eisai, Roche, and others.
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology…
More Releases for Bioparticles
CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Parti …
CD Bioparticles announces its advanced line of multiplex fluorescence particles.
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles announces its advanced line of multiplex fluorescence particles [https://www.cd-bioparticles.com/products/multiplex-assays-466.html] designed to streamline complex biological assays in flow cytometry experiments. These particles exhibit low signal widths in the forward scatter, side scatter and fluorescence channels. Various surface modifications, channels and sizes are also supported.
Flow cytometry is a convenient detection…
CD Bioparticles Introduces Functional Agarose Particles for Biomedical Research …
CD Bioparticles proudly announces the launch of its new Functional Agarose Particles.
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles proudly announces the launch of its new Functional Agarose Particles [https://www.cd-bioparticles.com/products/functional-agarose-particles-1065.html] designed for a variety of applications in the field of bioconjugation, isolation, and purification of biomacromolecules. These particles are ideal for researchers working in areas such as protein purification, antibody production, and nucleic acid isolation.
CD…
CD Bioparticles Announces Offering of Polystyrene Family Polymers for Drug Deliv …
CD Bioparticles announces the availability of Polystyrene Family polymers for a variety of drug delivery applications.
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is pleased to announce the availability of Polystyrene Family polymers [https://www.cd-bioparticles.net/polystyrene-family] for a variety of drug delivery applications. These polymers offer tunable physicochemical properties that enable sustained release profiles and improved drug bioavailability.
The polystyrene family, a group of polymers derived from…
CD Bioparticles Introduces New Polyolefin Family Polymers for Drug Delivery Appl …
CD Bioparticles announces Polyolefin Family polymers for a variety of drug delivery applications.
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has recently expanded its low PDI polymer portfolio and announces its new offering of Polyolefin Family [https://www.cd-bioparticles.net/polyolefin-family] polymers with a wide range of properties that make them well-suited for a variety of drug delivery applications.
Low dispersion index polymers are polymeric compounds with low molecular…
CD Bioparticles Introduces the Launch of Organic Gold Nanoparticles
With years of experience in the pharmaceutical and life science sector, CD Bioparticles now launches a comprehensive list of organic gold nanoparticles for research applications. These organic gold nanoparticles have a hydrophobic surface character and have great solubility in a wide range of organic solvents.
CD Bioparticles offers a comprehensive list of coatings, functional and conjugated gold nanoparticles through precise surface engineering. It offers gold nanoparticles functionalized with reactive groups such…
CD Bioparticles Expands Its Biodegradable Polymers Portfolio with Dendrimers
As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles recently introduces a series of dendrimers for research use, such as DMPA-G1-TMP-Acetylene, DMPA-G1-TMP-Azide, DMPA-G1-TMP-Carboxyl, and DMPA-G1-TMP-NHBOC. These biodegradable polymers can be used in theranostics, biosensors, optics, adhesives and coatings.
With customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms, CD Bioparticles can help scientists to solve problems in the…
